Follow The Filings

CRNX position history

The shares of Crinetics Pharmaceuticals In (CRNX) that FARALLON CAPITAL MANAGEMENT, L.L.C. reported in each quarter’s 13F.

Equity, COM

Shares held by quarter

New Add Reduce Exit

  1. 2023 Q3: 361,904 shares, $11M, 0.05% of portfolio, New
  2. 2023 Q4: 122,904 shares, $4.4M, 0.02% of portfolio, Reduce −66.0%
  3. 2024 Q1: 10,000 shares, $468K, <0.01% of portfolio, Reduce −91.9%
  4. 2024 Q2: 497,000 shares, $22M, 0.11% of portfolio, Add +4870.0%
  5. 2024 Q3: 1,162,000 shares, $59M, 0.29% of portfolio, Add +133.8%
  6. 2024 Q4: 4,075,098 shares, $208M, 1.1% of portfolio, Add +250.7%
  7. 2025 Q1: 4,605,098 shares, $154M, 0.86% of portfolio, Add +13.0%
  8. 2025 Q2: 4,646,098 shares, $134M, 0.58% of portfolio, Add +0.9%
  9. 2025 Q3: 11,540,196 shares, $481M, 2.0% of portfolio, Add +148.4%
  10. 2025 Q4: 6,933,098 shares, $323M, 1.5% of portfolio, Reduce −39.9%
  11. 2026 Q1: 8,338,098 shares, $303M, 1.7% of portfolio, Add +20.3%
  12. 2026 Q2: 8,989,098 shares, $336M, 1.6% of portfolio, Add +7.8%
Holdings date Value % of holdings Shares Filing date All 13F holders